52 results about "Ischemic Heart Diseases" patented technology

The invention relates to lauroyl cilostazol as well as a preparation method and application thereof. Wherein the lauroyl cilostazol is sterile, and preferably, the lauroyl cilostazol is a crystal. The invention further provides application of the lauroyl cilostazol in preparing medicines for treating cerebral infarction, cerebrovascular diseases, atherosclerosis, diabetic complications, peripheral vascular diseases, Reynolds diseases, intermittent claudication, ischemic heart diseases and acute coronary syndromes. The lauroyl cilostazol has the remarkable long-acting characteristic.

The invention discloses application of 9 ''-salvianolic acid B monomethyl ester in preparation of a medicine for treating ischemic heart disease, and belongs to the technical field of biological medicine. The CAS number of the 9 ''-salvianolic acid B monomethyl ester is 1167424-31-8, the ischemic heart disease refers to myocardial injury induced by heart ischemia reperfusion, and the invention further provides a pharmaceutical composition or a small molecule injection preparation. Animal experiments show that 9 ''-salvianolic acid B monomethyl ester is exogenously injected to relieve myocardial injury of a mouse and improve the heart function of the mouse, and it is proved that the medicine containing 9''-salvianolic acid B monomethyl ester can improve the ischemic heart disease, especially myocardial injury caused by heart ischemia reperfusion, and has a good application prospect. The invention provides potential drug selection and research direction for preventing and treating ischemic heart disease, and has important clinical application value.

The present invention provides, in part, a novel small molecule PHD inhibitor having a structure according to Formula (A) or a sub-formula thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein are useful in the treatment of diseases, including heart diseases (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung diseases (e.g., acute lung injury, pulmonary arterial hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver diseases (e.g., acute liver failure and liver fibrosis, and cirrhosis), and kidney diseases (e.g., acute liver failure, liver fibrosis, and cirrhosis). Acute kidney injury and chronic kidney disease).

The present invention discloses a hydrogel and its application in ischemic heart disease, relating to the technical field of myocardial infarction repair. The present invention provides a multifunctional hydrogel with injectability, enabling in-situ injection. This hydrogel combines the comprehensive characteristics of improving the conductivity of the infarcted area, generating oxygen, scavenging ROS, promoting M2 polarization of macrophages, and promoting angiogenesis. Its excellent performance is outstanding in alleviating MI / RI, improving the local microenvironment, and enhancing myocardial repair function, providing a new direction for the treatment of heart injury. At the same time, the CSA-δ hydrogel formed after loading drugs has the ability of drug sustained release, which enables the drugs to be released continuously and stably, thereby prolonging the drug action time.

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

The invention belongs to the technical field of new application of medicines, and provides application of Zhongwinning in preparation of a medicine for treating ischemic heart disease. In a myocardial ischemia rat model test, Zhongwinning shows that the Zhongwinning can obviously improve the left ventricular ejection fraction and the left ventricular short-axis shortening rate of a myocardial ischemia rat; in addition, the rising and falling rates of the ventricular pressure of the myocardial ischemia rats can be remarkably improved, and it is indicated that Zhongutanin can effectively recover the left ventricular systolic function and can effectively repair myocardial injury caused by myocardial ischemia reperfusion. Therefore, according to the experimental research result of the application, the Zhongwinning has a certain application prospect in treating the ischemic heart disease.

The invention provides application of S100A4 in preparation of a medicine for promoting myocardial cell proliferation. It is found that S100A4 not only can significantly induce proliferation of newborn mouse primary myocardial cells and hiPSC-CMs in vitro, but also can significantly improve the cardiac function after myocardial infarction and relieve ventricular fibrosis through AAV9-mediated cardiac targeting overexpression in vivo, and no obvious systemic toxic or side effect or tumorigenic signs are observed. Therefore, the S100A4 protein and the means of overexpressing the S100A4 can be used for promoting myocardial cell proliferation, so that the S100A4 protein can be used for improving or treating heart injury diseases such as ischemic heart disease and the like.

This application relates to the field of gene transduction technology, specifically disclosing a method and application for modifying mesenchymal stem cells (MSCs) targeting myocardial injury. The method includes: S1, obtaining umbilical cord-derived MSCs; S2, performing surface biomimetic modification on the MSCs; S3, gene editing on the MSCs; and S4, co-incubating the engineered MSCs with enzyme-responsive liposomes loaded with nitric oxide donors. The liposomes are embedded in a gelatin coating on the cell membrane surface through hydrophobic interactions, forming a targeted therapeutic system. This method for modifying MSCs targeting myocardial injury can be used for regenerative therapy and repair of myocardial injury diseases such as myocardial infarction and ischemic heart disease. It comprehensively improves the survival and stress tolerance of cells after implantation and enhances the targeting precision to the damaged site, thereby achieving the advantages of efficient, precise, and highly adaptable myocardial repair.

This invention belongs to the field of novel pharmaceutical applications, providing the application of Zhongwu Ning in the preparation of drugs for treating ischemic heart disease. In rat models of myocardial ischemia, Zhongwu Ning significantly increased the left ventricular ejection fraction and left ventricular fractional shortening rate; it also significantly improved the rate of increase and decrease of intracardiac pressure in rats with myocardial ischemia, indicating that Zhongwu Ning can effectively restore left ventricular systolic function and effectively repair myocardial damage caused by myocardial ischemia-reperfusion. Therefore, based on the experimental research results of this application, Zhongwu Ning has certain application prospects in the treatment of ischemic heart disease.

Disclosed herein is a method for detecting cardiomyopathy and heart failure in a subject, the method involving assaying a sample from the subject for decrease in gene or protein expression of a Obg Like ATPase 1 (OLA1) and / or the presence of a Y254C mutation in OLA1, thereby detecting cardiomyopathy and heart failure in the subject. Also disclosed is a method for treating cardiomyopathy, heart failure, myocardial infarction or heart attack, ischemic heart disease, coronary heart disease and hypertrophic cardiomyopathy in a subject, the method involving administering to the subject an expression vector comprising a nucleic acid sequence encoding wild-type Obg Like ATPase 1 (OLA1) operably linked to an expression control sequence.

Reganoxonin is used in the preparation of a drug for the detection of ischemic heart disease by echocardiography. Echocardiography is selected from one or more of stress echocardiography, myocardial angiography, transthoracic Doppler echocardiography, and two-dimensional speckle tracking echocardiography. Ischemic heart disease is selected from one or more of non-obstructive or obstructive ischemic heart disease. The diagnosis of the patient's disease by administering the drug has good accuracy, sensitivity, specificity, and safety.

The invention discloses an application of a compound in preparation of a medicine for treating cardiovascular diseases, the compound is SP3, and the structural formula is shown in the specification. The compound can obviously reduce the myocardial infarction area and ischemia area after myocardial ischemia reperfusion, has a myocardial protection effect, and particularly has a better effect on ischemic heart disease.

The invention relates to the technical field of medicines, in particular to application of an AKT inhibitor targeting FOXO in preparation of a medicine for promoting myocardial ischemic tissue angiogenesis and application of the AKT inhibitor in preparation of a medicine for treating ischemic heart diseases. In the cell level, the AKT inhibitor Ipatasertib can promote migration and tube formation of the HUVEC, and when the 6 [mu] M of Ipatasertib acts on the HUVEC, the expression of AKT can be significantly reduced, and the phosphorylation level of FOXO3 can be inhibited. In an in-vivo experiment, compared with a model group, a mouse in an Ipatasertib intervention group has the advantages that the left ventricular ejection fraction of an echocardiogram is remarkably increased, the myocardial infarction area is remarkably reduced, and the fluorescence density of an angiogenesis marker CD31 + is remarkably increased, so that the Ipatasertib can promote angiogenesis of a myocardial ischemia region of the mouse with acute myocardial infarction and rescue myocardial injury of the mouse.

The present invention relates to cytoprotective compounds and their uses. The present invention relates to cytoprotective, particularly cardioprotective and renoprotective organic compounds, preferably organic compounds that inhibit substrate phosphorylation caused by G protein-coupled receptor kinase 2 (GRK2, ADRBK1). Preferably, the organic compounds inhibit GRK2-mediated phosphorylation of serine / arginine-rich splicing factor 1 (SRSF1, ASF-1, SF2) and / or photosensory factors for the treatment of hypertension, heart disease, cardiac dysfunction or failure, and heart disease-related conditions such as cardiomyocyte necrosis, ischemic heart disease and / or ischemic heart injury or aging. In addition, the present invention relates to methods for identifying inhibitors of (GRK2)-mediated (SRSF1) and / or photosensory factor phosphorylation.

The present invention relates to inhibitors, and compositions containing inhibitors, and uses of the same in the treatment or prevention of a disease, disorder or condition related to HFrEF, such as an ischaemic heart disease, and / or HFpEF.

Ischemic heart disease is a leading cause of death and reduced quality of life worldwide. Although revascularization strategies significantly reduce mortality after acute myocardial infarction (MI), many patients with MI develop chronic heart failure over time. We previously reported that human recombinant ANGPTL4 counteracts ischemia-induced vascular endothelial growth factor signaling and disruption of endothelial cell-cell adhesion, thereby inhibiting vascular permeability. We were able to demonstrate that ANGPTL4 administration before MI resulted in protection of the coronary capillary network, no-reflow syndrome, and reduced infarct size in mice. We also demonstrated that the therapeutic effects observed with ANGPTL4 under ischemic conditions were caused by the FLD fragment, not the CCD fragment (WO 2016 / 110498). To further examine the therapeutic potential of the FLD fragment of ANGPTL4 at the onset of reperfusion, we herein used a porcine model, a clinically relevant model of acute myocardial infarction that can be easily and safely translated into patient treatment. We demonstrated that local (antegrade) delivery of the FLD ANGPTL4 to infarcted porcine hearts can efficiently target the lesion site in a clinically relevant manner. A single administration of the FLD of ANGPTL4 improved cardiac function, infarct size, fibrosis, and adverse remodeling parameters 28 days after MI. Short-term MI experiments, coupled with complementary mouse studies, demonstrated myocardial protection. Thus, a single administration of the FLD of ANGPTL4 can reduce ischemia-reperfusion injury and protect against adverse postischemic cardiac remodeling and subsequent ischemic heart failure.

The invention discloses an ischemic heart disease risk prediction method based on continuous physical examination data, and belongs to the technical field of biological information. Continuous physical examination data and time interval data of each physical examination are vectorized, and characterization learning is carried out on the continuous physical examination data and the time interval data through a time perception attention mechanism; different attention scores are given to each physical examination, physical examination index data and time interval data of the physical examination index data are fused, then the most significant fusion features are imported into a prediction layer for prediction, a cross entropy loss function is adopted to measure the relation between a prediction value and an actual measurement value, and the method is provided for improving the interpretability of classification. Mendel randomization analysis is used for analyzing the causal relationship between part of physical examination indexes and the ischemic heart disease so as to enhance the reliability of identifying disease risk factors by the model, and compared with a traditional method, the performance of the ischemic heart disease risk prediction model is improved, and the risk prediction accuracy of the ischemic heart disease is improved. And meanwhile, the interpretability of the model is enhanced.

A use of N-lactoyl-phenylalanine (Lac-Phe) in a preparation of a medicament for preventing and / or treating ischemic heart disease is provided. It is the first to demonstrate that Lac-Phe can improve the cardiac function in a mouse model of left anterior descending coronary artery stenosis, promote cardiac angiogenesis, improve the viability of hypoxic cardiomyocytes, and inhibit the expression of inflammatory cytokines in the heart, thereby playing an anti-myocardial ischemic injury role. Therefore, the Lac-Phe can be used to prepare a medicament for treating ischemic heart disease. A novel technical means for the treatment of ischemic heart disease is provided.

The present disclosure is directed to the treatment of ischemic heart disease and clinical conditions associated with ischemic heart disease. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in cardioprotective effects against acute myocardial infarction, such as a decrease in circulating triglycerides, total cholesterol, and low-density lipoproteins, and an increase in the ratio of high-density lipoprotein to total cholesterol.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating ischemic heart disease and a preparation method and application thereof. The traditional Chinese medicine composition is formed by compatibility of salvia miltiorrhiza and hawthorn, active functional components for protecting cardiac muscle in the salvia miltiorrhiza comprise water-soluble phenolic acids and fat-soluble tanshinone, and active functional components for protecting cardiac muscle in the hawthorn comprise procyanidins, flavonoids and triterpenic acids. Through systematic evaluation and research on the traditional Chinese medicine composition, the functional components for treating the IHD are screened out, the action mechanism of the functional components is clarified, and a new thought can be provided for precise treatment of the IHD.

The present invention discloses the application of a small molecule compound in ischemic heart disease, relating to the technical field of the treatment of ischemic heart disease. The CBX7 inhibitor is δ-Amyrenone. δ-Amyrenone can act as an inhibitor of the CBX7 protein, thereby regulating the cell cycle, inhibiting cell apoptosis, and promoting cardiomyocyte proliferation, and has good application prospects in the prevention and / or treatment of ischemic heart disease.

This invention discloses an acupoint therapy device for assisting in the improvement of ischemic heart disease, comprising a main body and two rings symmetrically arranged at both ends of the main body. One end of each ring is hinged to the main body, and the other end is a free end, with the free ends of the two rings movably connected. The main body includes a shell and a battery, a PCB circuit board, a CPU (central processing unit), and a power amplifier mounted on the PCB circuit board within the shell. A pulsed magnetic field transmitter is located near the palm inside the shell. The signal output terminal of the CPU is connected to the signal input terminal of the power amplifier, and the signal output terminal of the power amplifier is connected to the signal input terminal of the pulsed magnetic field transmitter. A power switch is provided on the shell. This acupoint therapy device for assisting in the improvement of ischemic heart disease has the advantages of being non-invasive, painless, portable, intelligently operated, and having high compliance.

The invention relates to the technical field of medicines, in particular to ROS-triggered hydrogen sulfide donor derivatives as well as a preparation method and application thereof. The synthesis method of the beta-carboline hydrogen sulfide donor derivative is simple, and the beta-carboline hydrogen sulfide donor with dual functions can be obtained by condensing 4-phenylboronic acid pinacol ester thiobenzyl alcohol and different 3-position isothiocyanate substituted beta-carboline derivatives. The compound can recognize excessive oxygen free radicals generated in the myocardial ischemia reperfusion process, release hydrogen sulfide with a vascular protection effect and beta-carboline derivatives with myocardial protection activity at the same time, protect damaged myocardium from two aspects at the same time, have small influence on normal cells, and can be used for preparing a medicine for treating myocardial ischemia. And a new choice is provided for research and development of ischemic heart disease treatment drugs.

Part of this invention provides novel small molecule PHD inhibitors having structures according to formula (I) and its derivatives: or pharmaceutically acceptable salts thereof. The compounds provided herein may be used to treat the following diseases: including heart diseases (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung diseases (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory diseases (e.g., respiratory infections, acute respiratory distress syndrome), liver diseases (e.g., acute liver failure, liver fibrosis, and cirrhosis), and kidney diseases (e.g., acute kidney injury and chronic kidney disease), inflammatory bowel disease (IBD), ischemic-reperfusion injury (e.g., stroke), and retinopathy of prematurity (ROP).

The present invention provides, in part, a novel small molecule PHD inhibitor having a structure according to Formula (A) or a sub-formula thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein are useful in the treatment of diseases, including heart diseases (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung diseases (e.g., acute lung injury, pulmonary arterial hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver diseases (e.g., acute liver failure and liver fibrosis, and cirrhosis), and kidney diseases (e.g., acute liver failure, liver fibrosis, and cirrhosis). Acute kidney injury and chronic kidney disease).

The present invention provides, in part, novel small molecule PHD inhibitors having a structure according to Formula (A) or its subformulas: or a pharmaceutically acceptable salt thereof. The compounds provided herein are useful for treating diseases including heart disease (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung disease (e.g., acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver disease (e.g., acute liver failure and liver fibrosis and cirrhosis), and kidney disease (e.g., acute kidney injury and chronic kidney disease). #imgabs0#

The invention relates to the technical field of disease treatment, in particular to application of cardiac macrophage USP9X serving as an intervention target to preparation of medicine for treating ischemic heart disease, polypeptide P7 and application of the polypeptide P7. The invention finds that the expression of Ubiquitin specific peptidase 9X-Linked, USP9X coupled with deubiquitinase X chromosome of heart macrophage is reduced in the first three days (inflammation period) after myocardial infarction, and the inhibition of USP9X promotes the macrophage to be transformed into proinflammatory type, and finally causes poor ventricular remodeling, so that the USP9X can be used as an intervention target of ischemic heart disease, and then polypeptide is screened, and the application of the USP9X in the treatment of ischemic heart disease is realized. The degradation of USP9X after myocardial infarction is effectively inhibited, so that the excessive inflammatory response of macrophages after myocardial infarction is relieved.

The present invention relates to the field of medicinal chemistry and specifically discloses a compound, a composition, and their use in preparing a medicament for treating heart disease. The compound is dihydroanemulyl acetate, isosaxifen, or lindera lactone. The composition comprises dihydroanemulyl acetate, isosaxifen, and lindera lactone. Studies have shown that compounds such as dihydroanemulyl acetate, isosaxifen, and lindera lactone have therapeutic effects on ischemic heart disease. Therefore, using dihydroanemulyl acetate, isosaxifen, or lindera lactone, or a combination thereof, as an active ingredient in preparing a medicament for treating heart disease has important application value.

The invention relates to the technical field of biological medicines, and particularly discloses application of sarcosine in preparation of a medicine for treating ischemic heart disease. According to the technical scheme provided by the invention, the expression of HIF1-alpha protein can be remarkably increased through sarcosine, so that angiogenesis is enhanced, the heart function of the ischemic heart disease is improved, ventricular remodeling is relieved, and the ischemic heart disease can be effectively prevented and / or treated.

The invention relates to the technical field of nucleic acid drugs and gene therapy, in particular to a preparation method and application of endothelial cell specific modRNA. The system comprises a number 1 modRNA and a number 2 modRNA, the number 1 modRNA encodes a target protein, a 5 '-untranslated region of the number 1 modRNA comprises an L7Ae protein binding element k-turn, the number 2 modRNA encodes an L7Ae protein, a 3'-untranslated region of the number 2 modRNA comprises at least one miR126 recognition sequence, and the number 1 modRNA and the number 2 modRNA are used for being delivered into an endothelial cell; the system has no genome integration risk, the expression is regulated and controlled by miR126 in real time, and the system is suitable for vascular regeneration of targeted endothelial cells, precise gene therapy of ischemic heart disease and the like.